Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence

Jeffrey T. Jensen, Schlaff W, William D. Schlaff, William Schlaff, Gordon K, Keith Gordon
Fertility and sterility · 2018 · vol. 110(1) , pp. 137–152.e1 · doi:10.1016/j.fertnstert.2018.03.012 · PMID:29937152 · W2809363466
review OA: hybrid CC0 ⤵ 73 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

This systematic review found combined hormonal contraceptives reduce endometriosis-related pain, but the low-quality evidence necessitates further high-quality studies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To review the available clinical evidence on the use of combined hormonal contraceptive (CHC) agents (estrogen [E]-progestin combinations) for the treatment of endometriosis-related pain. DESIGN: A systematic review of the MEDLINE, Embase, and Derwent Drug File databases for prospective clinical studies. SETTING: Not applicable. PATIENT(S): Women with endometriosis diagnosed by validated means. INTERVENTION(S): Combined hormonal contraceptive agents, active comparators, placebo, or no treatment. MAIN OUTCOME MEASURE(S): Endometriosis-related pain (dysmenorrhea, pelvic pain, and dyspareunia). RESULT(S): Nine randomized controlled trials and nine observational studies met the inclusion criteria. The quality of data was low: only two of the nine randomized trials were placebo controlled, and most trials were not blinded. The CHC agents were reported to significantly reduce dysmenorrhea, pelvic pain, and dyspareunia from baseline in most studies; continuous administration seemed to be more useful than cyclic administration. The effectiveness of CHC agents for pain reduction was similar to or less than that of oral progestins and GnRH agonists. CONCLUSION(S): The available literature suggests that CHC treatment is effective for relief of endometriosis-related dysmenorrhea, pelvic pain, and dyspareunia; however, the supportive data are of low quality. Furthermore, insufficient data exist to reach conclusions about the overall superiority of any given CHC therapy, and the relative benefit in comparison to other approaches. Additional high-quality studies are needed to clarify the role of CHC agents and other treatments in women with endometriosis-related pain.

My notes (saved in your browser only)

Condition tags

dysmenorrheadyspareuniaendometriosischronic_pelvic_pain

MeSH descriptors

Analgesics Contraceptives, Oral, Combined Contraceptives, Oral, Hormonal Dysmenorrhea Dyspareunia Endometriosis Pelvic Pain Analgesics Analgesics Contraceptives, Oral, Combined Contraceptives, Oral, Combined Contraceptives, Oral, Hormonal Contraceptives, Oral, Hormonal Dysmenorrhea Dysmenorrhea Dysmenorrhea Dyspareunia Dyspareunia Dyspareunia Endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (51)

Cited by (50)

Source provenance

europepmc
last seen: 2026-09-05T06:14:40.014199+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:43.094626+00:00
License: CC0 · commercial use OK